Oncology Corporate Profile
4SC discovers and develops targeted small-molecule drugs for the treatment of diseases with a high unmet medical need in various autoimmune and cancer indications. These drugs are intended to provide patients with innovative treatment options that are more tolerable and efficacious than existing therapies, and provide a better quality of life. The company's balanced pipeline comprises promising products that are in various stages of clinical development. 4SC's aim is to generate future growth and enhance its enterprise value by entering into partnerships with leading pharmaceutical companies.
Website: http://www.4sc.de/
Brand / Product | Class | Area of Study | Phase | Partnership |
---|---|---|---|---|
resminostat / 4SC-201 | HDAC inhibitor | 2nd line metastatic Hepatocellular Carcinoma (HCC) | II | Yakult |
resminostat / 4SC-201 | HDAC inhibitor | 3rd line metastatic Hodgkin's Lymphoma | II | |
resminostat (+ sorafenib) / 4SC-201 | HDAC inhibitor | Cutaneous T-cell Lymphoma (CTCL) | II | Yakult |
resminostat / 4SC-201 | HDAC inhibitor | 2nd line metastatic Colorectal Cancer | I | Yakult |
4SC-202 | HDAC inhibitor | Various cancer types | I |
View additional information on product candidates here »